FY2024 Earnings Estimate for SAGE Issued By HC Wainwright

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Equities research analysts at HC Wainwright dropped their FY2024 EPS estimates for Sage Therapeutics in a research report issued on Wednesday, October 30th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings per share of ($6.72) for the year, down from their previous forecast of ($6.58). HC Wainwright currently has a “Neutral” rating and a $14.00 price target on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.43) per share. HC Wainwright also issued estimates for Sage Therapeutics’ Q4 2024 earnings at ($1.69) EPS, Q1 2025 earnings at ($1.54) EPS, Q2 2025 earnings at ($1.30) EPS, Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($4.78) EPS, FY2026 earnings at ($3.63) EPS and FY2027 earnings at ($2.87) EPS.

SAGE has been the subject of a number of other research reports. Raymond James restated a “market perform” rating on shares of Sage Therapeutics in a research report on Thursday, October 10th. StockNews.com cut shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. Mizuho cut their target price on shares of Sage Therapeutics from $18.00 to $16.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Royal Bank of Canada cut shares of Sage Therapeutics from an “outperform” rating to a “sector perform” rating and cut their target price for the stock from $10.00 to $4.00 in a research report on Friday, October 4th. Finally, Bank of America cut their price objective on shares of Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating for the company in a research report on Wednesday, October 9th. Three research analysts have rated the stock with a sell rating, seventeen have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Sage Therapeutics presently has an average rating of “Hold” and an average price target of $12.89.

Sage Therapeutics Trading Down 0.5 %

Shares of SAGE opened at $6.05 on Friday. The stock has a market cap of $370.10 million, a P/E ratio of -1.08 and a beta of 0.91. The company has a 50-day moving average of $7.44 and a two-hundred day moving average of $9.95. Sage Therapeutics has a 12-month low of $5.84 and a 12-month high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The company had revenue of $11.87 million during the quarter, compared to analyst estimates of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The firm’s revenue for the quarter was up 337.1% on a year-over-year basis. During the same quarter last year, the business earned ($2.81) EPS.

Institutional Investors Weigh In On Sage Therapeutics

Several institutional investors have recently bought and sold shares of SAGE. Vanguard Group Inc. grew its stake in Sage Therapeutics by 2.1% during the fourth quarter. Vanguard Group Inc. now owns 5,319,360 shares of the biopharmaceutical company’s stock worth $115,271,000 after buying an additional 111,358 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Sage Therapeutics by 4.6% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 38,568 shares of the biopharmaceutical company’s stock worth $723,000 after buying an additional 1,693 shares during the period. Inspire Investing LLC grew its stake in Sage Therapeutics by 9.4% during the first quarter. Inspire Investing LLC now owns 19,234 shares of the biopharmaceutical company’s stock worth $360,000 after buying an additional 1,652 shares during the period. ProShare Advisors LLC grew its stake in Sage Therapeutics by 9.0% during the first quarter. ProShare Advisors LLC now owns 13,713 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 1,130 shares during the period. Finally, State Board of Administration of Florida Retirement System grew its stake in Sage Therapeutics by 9.8% during the first quarter. State Board of Administration of Florida Retirement System now owns 16,644 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 1,480 shares during the period. 99.22% of the stock is currently owned by hedge funds and other institutional investors.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.